Innovations Continue to Drive Market Gains
Over $50B in Product Sales Have Been Posted in the Last 20 Years as a Result of Biotech Advances Biotechnology stocks were up about 12% over the past 12 months through February 2011, underperforming the Nasdaq, which was up 29%. The NYSE Arca Biotech ETF did better, up 23%. Since the recent...
Life Science Stocks Rally into the Third Day Up Over 2%
Risk is on for Life Science Stocks The rally that began late tuesday continued into the third day with major biotech indices up over 2%.The Rayno Life Science Portfolio was up 2.2% with recent reiterated buys up even more: AMRI, EXAS, GPRO, OPTR, REGN, SGEN, and VPHM. Illumina (ILMN $39.93)...
Another Wild Day: Market Roars Back in Final 40 Minutes
Market Turns Up at 3:18 EDT for 2.28% Gain in S&P: 1080 is the mark for a 2011 bottom After a roller coaster day where stocks were ready to break the scary 1080 level on the S&P, it abruptly reversed course for a 4.1% gain from the bottom. As usual the headline (or shall we say quote)...
Sell-Off Breaks Through August 9 Technical Bottom: Biotechs Weak
Concerns About The Global Economy And Massive Debt Bring Us To Bear Market Boundaries The first day of the fourth quarter of 2011 held out hope for a new market direction, but the relentless selling from Q3 persisted with the major averages off more than 2.5%. The market tried to rally in the...
Rally Rolls Over: Trading Range Intact-Biotech Outperforms in September
A 2.7+% rally faded today as European debt crisis headlines put a damper on optimism. Many of the pundits were skeptical of the rally saying it was driven by short covering. Biotechs Outperforming This Month With all of this volatility you'd think we found a trend. But the three day rally has...